Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roducitabine - Opus Genetics

Next Previous
Drug Profile

Roducitabine - Opus Genetics

Alternative Names: FCPEC; Fluorocyclopentenylcytosine; NGC-Gemcitabine; PCS-3117; RX 3117; TV-1360

Latest Information Update: 24 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Developer Opus Genetics; Processa Pharmaceuticals; Rexahn Pharmaceuticals
  • Class Antineoplastics; Cyclopentanes; Fluorinated hydrocarbons; Nucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bladder cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 22 Oct 2024 Ocuphire Pharma has merged with Opus Genetics to form Opus Genetics
  • 29 Nov 2023 Processa Pharmaceuticals expects discussion with FDA for phase IIb/IIIa trial in first half of 2024
  • 07 Sep 2023 Phase-II clinical trials in Solid tumours in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top